IOL Chemicals & Pharmaceuticals
add_icon

IOL Chemicals & Pharmaceuticals

89.11
-0.84
(-0.93%)
Market Cap
₹- Cr
PE Ratio
-
Volume
4,21,152.00
Day High - Low
₹90.01 - ₹88.86
52W High-Low
₹126.66 - ₹57.50
hide
Key Fundamentals
Add Ratio
split_icon_default
Market Cap
- Cr
EPS
-
PB Ratio
-
Book Value
59.66
EBITDA
-
Dividend Yield
- %
Industry
Healthcare
ROE Growth %
-
Debt to Equity
-
Analyst Rating and Forecast
- By Refinitiv from2 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+100.00 %
+100.00 %
Hold
Hold0.0 %
0.0 %
Sell
Sell0.0 %
0.0 %
Forecast For
Actual

Company News

View All News
Caret
positive
IOL Chemicals achieved revenue of INR 567.5 crores with 7.9% year-on-year growth and EBITDA expansion to 11.1% margins, driven by volume recovery in non-Ibuprofen APIs and paracetamol capacity utilization reaching 55%. The company faced temporary margin pressure from INR 7-8 crores in elevated fuel costs due to Punjab floods but expects normalization in coming quarters while targeting 13-14% EBITDA margins.
positive
IOL Chemicals & Pharmaceuticals is targeting growth through capacity expansion in ibuprofen and specialty chemicals. The company is implementing backward integration to drive cost efficiency and developing new molecules for API diversification. The strategy includes margin improvement initiatives through energy savings and green chemistry programs. The company reports having a strong export order pipeline.
neutral
IOL Chemicals and Pharmaceuticals Limited reported a net profit of ₹30.00 crore for the quarter ended September 30, 2025, compared to ₹33.96 crore in the previous quarter, representing a decline of 11.7%. However, revenue from operations increased to ₹567.53 crore from ₹551.69 crore in the previous quarter. For the half-year period, net profit reached ₹63.96 crore on revenue of ₹1,119.22 crore. The company operates in two segments - Pharmaceuticals and Chemicals. Total expenses for the quarter were ₹533.89 crore, with cost of materials consumed being the largest component at ₹376.55 crore. The Board of Directors approved these unaudited financial results at their meeting held on November 11, 2025.
View more
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
185.27
-
#1 -
-
-
-
-
36.05
942.70
-
#1 -
-
-
-
-
45.40
672.70
-
#1 -
-
-
-
-
30.22
29,240.00
-
#1 -
-
-
-
-
43.51
71.32
-
#1 -
-
-
-
-
46.19
1,604.00
-
#1 -
-
-
-
-
54.09
746.10
-
#1 -
-
-
-
-
46.49
216.12
-
#1 -
-
-
-
-
45.44
1,429.30
-
#1 -
-
-
-
-
56.86
545.60
-
#1 -
-
-
-
-
16.55
Growth Rate
Revenue Growth
-
Net Income Growth
-
Cash Flow Change
-
ROE
-
ROCE
-
EBITDA Margin (Avg.)
-

Quarterly Financial Results

Quarterly Financials
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Revenue
579
570
547
530
596
570
552
529
511
510
532
527
532
559
574
Expenses
527
509
510
481
492
491
481
476
454
451
484
476
465
490
511
EBITDA
52
61
37
49
104
80
71
53
57
59
48
51
67
70
64
Operating Profit %
8 %
10 %
6 %
8 %
16 %
13 %
12 %
9 %
10 %
10 %
8 %
9 %
12 %
11 %
10 %
Depreciation
11
11
11
12
12
14
16
16
16
17
18
19
19
20
20
Interest
2
3
4
5
5
4
4
4
3
2
4
5
4
4
4
Profit Before Tax
39
47
22
33
87
61
51
32
37
40
26
28
45
46
41
Tax
9
12
6
9
22
15
13
9
10
10
7
7
13
12
11
Net Profit
30
35
16
24
65
46
38
23
28
30
19
21
31
34
30
EPS in ₹
5.07
5.91
2.71
4.05
11.03
7.81
6.45
3.93
4.71
5.11
3.26
3.50
1.07
1.16
1.02

Balance Sheet

Balance Sheet
2022
2023
2024
2025
Total Assets
1,962
2,022
2,244
2,382
Fixed Assets
561
752
933
1,171
Current Assets
1,081
920
1,120
1,151
Capital Work in Progress
105
90
101
22
Investments
2
20
20
21
Other Assets
1,294
1,161
1,190
1,169
Total Liabilities
1,962
2,022
2,244
2,382
Current Liabilities
513
456
560
610
Non Current Liabilities
57
58
73
85
Total Equity
1,392
1,508
1,612
1,688
Reserve & Surplus
1,334
1,449
1,553
1,629
Share Capital
59
59
59
59

Cash Flow

Cash Flow
2022
2023
2024
2025
Net Cash Flow
-29
-2
6
71
Investing Activities
-121
-120
-191
-154
Operating Activities
93
122
290
179
Financing Activities
-2
-4
-93
46

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Promoter
43.69 %
43.69 %
43.69 %
43.69 %
43.69 %
43.69 %
43.69 %
43.69 %
48.19 %
48.19 %
48.19 %
48.19 %
48.19 %
48.19 %
48.19 %
52.62 %
52.62 %
52.62 %
52.62 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
2.34 %
2.18 %
1.41 %
1.39 %
1.63 %
1.49 %
1.47 %
2.59 %
2.25 %
DIIs
0.04 %
0.04 %
0.36 %
0.50 %
0.02 %
0.02 %
0.06 %
0.17 %
0.02 %
0.26 %
0.36 %
0.37 %
0.30 %
0.10 %
0.08 %
0.08 %
0.07 %
0.02 %
0.04 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
27.30 %
28.03 %
29.86 %
30.15 %
30.29 %
31.15 %
31.15 %
30.92 %
30.49 %
29.28 %
30.28 %
30.63 %
30.98 %
31.48 %
31.31 %
31.23 %
31.43 %
30.22 %
29.97 %
Others
28.97 %
28.24 %
26.08 %
25.66 %
25.99 %
25.14 %
25.10 %
25.23 %
21.30 %
22.26 %
18.84 %
18.62 %
19.12 %
18.84 %
18.79 %
14.58 %
14.40 %
14.54 %
15.12 %
No of Share Holders
1,09,092
1,27,893
1,42,022
1,45,041
1,46,437
1,48,907
1,45,692
1,43,327
1,40,177
1,26,004
1,35,397
1,34,235
1,30,003
1,28,689
1,25,979
1,26,701
1,30,002
1,25,040
1,36,129

Dividend History

Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 0.00 0.00 0.00 3 6 4 4 5 0.8
Dividend Yield (%) 0.00 0.00 0.00 0.00 2.72 8.48 7.07 5.53 8.18 0.89

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
12 Sept 2021 DIVIDEND Dividend
₹ 2.00 /share
08 Sept 2021 142.80 110.43
16 Feb 2022 DIVIDEND Dividend
₹ 4.00 /share
15 Feb 2022 91.71 77.42
17 Feb 2023 DIVIDEND Dividend
₹ 4.00 /share
17 Feb 2023 62.59 63.30
16 Feb 2024 DIVIDEND Dividend
₹ 5.00 /share
16 Feb 2024 87.56 82.25
23 Aug 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
23 Aug 2024 74.72 93.30
14 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
14 Nov 2024 79.07 74.06
12 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
12 Feb 2025 72.62 73.57
18 Feb 2025 DIVIDEND Dividend
₹ 4.00 /share
18 Feb 2025 73.57 68.18
27 Dec 2024 SPLIT Split
2:10
11 Mar 2025 82.27 82.27
16 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
16 May 2025 65.00 77.10
07 Aug 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
07 Aug 2025 94.23 95.10
22 Aug 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
22 Aug 2025 77.10 98.25
11 Nov 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
11 Nov 2025 94.32 89.30

Announcements

Announcement under Regulation 30 (LODR)-Newspaper Publication6 days ago
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 19, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 13, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationNov 12, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 12, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 11, 2025
Un-Audited Financial Results For The Quarter And Half Year Ended 30Th September 2025Nov 11, 2025
Board Meeting Outcome for Outcome Of The Board Meeting And Submission Of Un-Audited Financial Results For The Quarter And Half Year Ended 30Th September 2025Nov 11, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 10, 2025
Board Meeting Intimation for Notice Of Board MeetingNov 04, 2025
EDQM Issued CEP Certificate For Sitagliptin Phosphate MonohydrateOct 27, 2025
Intimation Of Incorporation Of Wholly Owned SubsidiaryOct 24, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Oct 18, 2025
EDQM Issued CEP Certificate For Pantoprazole Sodium Sesquihydrate Process-IIIOct 15, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 07, 2025
Intimation On Receipt Of Request For Re-Lodgement Of Transfer Requests Of Physical SharesOct 01, 2025
Closure of Trading WindowSep 26, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 25, 2025
Dispatch Of Reminder Letter To Shareholders To Update KYCSep 24, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 09, 2025
Clarification On Volume MovementSep 09, 2025
Clarification sought from IOL Chemicals & Pharmaceuticals LtdSep 09, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 29, 2025
Shareholder Meeting / Postal Ballot-Scrutinizers ReportAug 22, 2025
Shareholder Meeting / Postal Ballot-Outcome of AGMAug 22, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 13, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 12, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 12, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 08, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 08, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationAug 07, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 07, 2025
Board Meeting Outcome for Outcome Of The Board Meeting And Submission Of Un-Audited Financial Results For The Quarter Ended 30Th June 2025Aug 07, 2025
Un-Audited Financial Results For The Quarter Ended 30Th June 2025Aug 07, 2025
Intimation Pursuant To Regulation 36(1)(B) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015Aug 05, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 04, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 04, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 01, 2025
Business Responsibility and Sustainability Reporting (BRSR)Jul 31, 2025
Reg. 34 (1) Annual Report.Jul 31, 2025
Notice Of 38Th Annual General Meeting (AGM) Of The CompanyJul 31, 2025
Board Meeting Intimation for Notice Of The Board MeetingJul 28, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 22, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 22, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 15, 2025
Announcement under Regulation 30 (LODR)-Credit RatingJul 01, 2025
Closure of Trading WindowJun 26, 2025
REACH Registration For Acetic AnhydrideJun 13, 2025
IOL Awarded Ecovadis Silver Medal - Ranks Among The Top 15% Companies GloballyJun 11, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 27, 2025

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
Bandhan BSE Healthcare Index Fund Direct-Growth
0.08%
8
-0.01%
0.00%

Technical Indicators